未名医药(002581) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for the first quarter of 2024 was ¥83,804,783.29, representing a 10.85% increase compared to ¥75,602,502.59 in the same period last year[35]. - The net loss attributable to shareholders for the first quarter was ¥27,704,081.15, which is a 28.82% increase in loss from ¥21,505,965.06 year-over-year[35]. - The company's retained earnings decreased to ¥785,163,604.86 from ¥812,867,686.01[51]. - The company recorded a net profit of RMB -27,055,340.81, compared to RMB -21,379,098.60 in the same period last year, reflecting a 27% increase in net loss[79]. - The company’s operating profit was reported at RMB -27,947,839.97, worsening from RMB -21,146,063.02 in the previous period[79]. - The company’s basic and diluted earnings per share were both reported at RMB -0.0420, compared to RMB -0.0326 in the previous period[79]. Cash Flow and Liquidity - The cash balance increased by 41.77% compared to the beginning of the year, primarily due to dividend receipts[8]. - The net cash flow from operating activities improved by 47.23%, amounting to -¥15,200,975.67 compared to -¥28,808,307.94 in the previous year[35]. - The cash and cash equivalents at the end of the period were ¥215,248,425.84, compared to ¥70,057,037.42 at the end of the previous period[54]. - The cash inflow from investment activities was RMB 78,870,135.54, compared to RMB 2,161,278.00 in the previous period, indicating a substantial increase[77]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 35,398[13]. - The largest shareholder, Gao Baolin, holds 11.19% of the shares, totaling 73,822,800 shares[13]. - The company plans to reduce shares by up to 39,584,135 shares, which is 6% of the total share capital, but the reduction plan has not been executed as of the report date[69]. Regulatory and Compliance Issues - The company received a warning letter from the China Securities Regulatory Commission regarding non-disclosure of related party transactions and inaccurate performance forecasts[16]. - The company received a notice of case filing from the China Securities Regulatory Commission for suspected violations of information disclosure regulations[47]. - The company is committed to ensuring the accuracy and completeness of its information disclosure[2]. Asset and Liability Management - Total assets at the end of the reporting period were ¥2,255,947,217.63, a decrease of 3.47% from ¥2,337,137,949.03 at the end of the previous year[35]. - The equity attributable to shareholders decreased by 1.03%, totaling ¥2,047,162,710.74 compared to ¥2,068,467,729.91 at the end of the last year[35]. - Total liabilities decreased to ¥102,877,145.16 from ¥163,411,597.73, indicating a significant reduction[51]. - Non-current liabilities totaled ¥27,032,180.67, down from ¥29,803,542.40 in the previous period[51]. Revenue and Expense Analysis - Total operating revenue for the current period reached ¥83,804,783.29, an increase of 10.3% compared to ¥75,602,502.59 in the previous period[51]. - Total operating costs amounted to ¥106,361,412.35, up from ¥104,535,537.78, reflecting a rise of 1.75%[51]. - Financial expenses decreased by 109.61% compared to the same period last year, primarily due to reduced borrowing costs[40]. - Investment income decreased by 201.77% compared to the same period last year, mainly due to a decline in investment income from joint ventures[11]. - Non-operating income increased by 5335.55% compared to the same period last year, primarily due to debt discounts[12]. Receivables and Payables Management - Other receivables decreased by 31.17% compared to the beginning of the year, mainly due to the recovery of funds[9]. - The balance of accounts receivable financing decreased by 30.91% compared to the beginning of the year, primarily due to increased collection efforts[38]. - The balance of employee compensation payable decreased by 65.97% compared to the beginning of the year, mainly due to salary payments made during the period[39]. - The balance of accounts payable decreased by 49.94% compared to the beginning of the year, primarily due to payments made for purchases[62]. - The balance of receivables decreased by 60.24% compared to the beginning of the year, attributed to increased collection efforts[61]. - Credit impairment losses increased by 454.20% compared to the same period last year, mainly due to provisions for impairment[64].